Fatal natural killer cell lymphoma arising in a patient with a crop of Epstein-Barr virus-associated disorders

European Journal of Dermatology

Volumn 15, Issue 6, 2005, Pages 503-506

  Nitta, Yukiko ^a   Iwatsuki, Keiji ^b   Kimura, Hiroshi ^c   Kojima, Seiji ^c   Moroshima, Tsuneo ^b   Tsuji, Kazuhide ^b   Oono, Takashi ^b  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EB virus; Haemophagocytosis; Hydroa vacciniforme; Mosquito bite; Nasal lymphoma; Natural killer cell

Indexed keywords

ACICLOVIR; PREDNISOLONE;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANAMNESIS; ARTICLE; ASIAN; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; INSECT BITE; LABORATORY TEST; LONG TERM CARE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOSQUITO; NATURAL KILLER CELL LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; SKIN DISEASE; T CELL LYMPHOMA; TUMOR BIOPSY; VIRUS INFECTION;

ADOLESCENT; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA;

EID: 28244491597     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Tokura Y, Ishhara S, Tagawa S, Seo N, Ohshima K, Takigawa H. Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus associated natural killer cell leukemia/lympnoma. J Am Acad Dermatol 2001; 45: 568-9.
2. Tsuge I, Morishita T, Morita H, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr (EBV)-infected natural killer (NK) cell proliferation in patient with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 1999; 115: 385-92.
3. Satoh M, Oyama N, Akiba H, Ohtsuka M, Iwatsuki K, Kaneko F. Hypersensitivity to mosquito bites with natural-killer cell lymphocytosis: the possible implication of Epstein-Barr virus reactivation. Eur J Dermatol 2002; 12: 381-4.
4. Asada H, Miyagawa S, Sumikawa Y, Yamaguchi Y, Itami S, Suguri S, et al. CD4+ T-lymphocyte-induced Epstein-Barr virus reactivation in a patient with severe hypersensitivity to mosquito bites and Epstein-Barr virus-infected NK cell lymphocytosis. Arch Dermatol 2003; 139: 1601-7.
5. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, Morishima T. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 15(98): 280-6.
6. Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al., Japanese Association for Research on Epstein-Barr Virus and Related Diseases. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527-33.
7. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002; 44: 259-72.
8. Oono T, Arata J, Masuda T, Ohtsuki Y. Coexistence of hydroa vacciniforme and malignant lymphoma. Arch Dermatol 1986; 122: 1306-9.
9. Iwatsuki K, Ohtsuka M, Harada H, Ham G, Kaneko F. Clinicopathologic manifestations of Epstein-Barr virus associated cutaneous lymphoproliferative disorders. Arch Dermatol 1997; 133: 1081-6.
10. Iwatsuki K, Xu Z, Takata M, Iguchi M, Ohtsuka M, Akiba H. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999; 140: 715-21.
11. Cho KH, Kim CW, Lee DY, Sohn SJ. An Epstein-Barr virus-associated lymphoproliferative lesion of the skin presenting as recurrent necrotic papulovesicles of the face. Br J Dermatol 1996; 134: 791-6.
12. Magana M, Sangueza P, Gil-Beristain J, Sanchez-Sosa S, Salgado A, Romon G, et al. Angiocentric cutaneous T-cell lymphoma of children (hydroa-like lymphoma): A distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 574-9.
13. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990; 335: 128-30.
14. Iwatsuki K, Yamamoto T, Tsuji K, Suzuki D, Fujii K, Matuura H, et al. A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Acta Med Okayama 2004: 169-80.
15. Ohtsuka M, Iwatsuki K, Kaneko R, Akiba H, Kikuchi S, Harada H, et al. Epstein-Barr virus-associated lymphoid hyperplasia of the eyelid characterized by intramuscular infiltration. Br J Dermatol 1999; 140: 358-9.
16. Cho KH, Lee SH, Kim CW, Jeon YK, Kwon IH, Cho YJ, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol 2004; 151: 372-80.
17. Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Semin Hematol2003; 40: 124-32.
18. Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, et al. Differential celluar targets of Epstein-Barr virus (EBV) infection between acute EBV-associated haemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882-8.